Press Releases

Erstmals in Deutschland vorgestelltDie anhaltende infarktbedingte Herzschwäche besitzt weltweit eine hohe klinische Bedeutung, typisch sind eine erhöhte Sterblichkeitsrate und wiederkehrende stationäre Krankenhausaufent-halte.Patienten nach einem Herzinfarkt entwickeln trotz leitliniengerechter Herzschwäche-Therapien oft fortschreitende Herzschwäche-Symptome, die auch auf einer Narbenbildung am Herzmuskel be-ruhen können.Die Prognose dieser Erkrankung ist ungünstig: Ca. 50 % der [...]

SAN RAMON, Calif. — March 9, 2020 — BioVentrix, Inc., developer of the first hybrid transcatheter device for left ventricular remodeling after a heart attack, today announced that it has been named by FierceMedTech as one of the “Fierce 15” for 2019, designating it as one of the most promising [...]

San Ramon, Kalifornien – 4. März 2020 – BioVentrix, Inc., Hersteller des ersten katheter-basierten Systems zum linksventrikulären Remodeling nach Herzinfarkt, hat heute bekannt-gegeben, dass Dr. med. Ralph Stephan von Bardeleben vom Universitätsklinikum Mainz als Co-Principal Investigator bei der in Europa durchgeführten klinischen Studie REVIVE-HF zur Less Invasive Ventricular Enhancement (LIVETM)-Therapie [...]

REVIVE-HF seeks to demonstrate superiority of the Revivent TC System to current guideline treatment for heart failureSAN RAMON, Calif.--(BUSINESS WIRE)--BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced that Ralph Stephan von Bardeleben, MD, of the University Medical Center of Mainz [...]

SAN RAMON, Calif. – February 18, 2020 – BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), today announced that Gregg Stone, MD, of New York’s Mount Sinai Health System has signed on to the pivotal ALIVE Trial of the Revivent TC™ [...]

Für Herzinfarkt-Patienten ist die innovative LIVE™-Therapie (Less Invasive Ventricular Enhancement) schonender als eine herkömmliche Operation, und sie verbessert nachweislich sowohl die Herzleistung als auch die Lebensqualität der Betroffenen.Die Zahl der Zentren, die dieses Verfahren anbieten, nimmt stetig zu. Jüngstes Beispiel ist das Asklepios Klinikum Harburg, das kürzlich die LIVE™-Therapie erfolgreich [...]

San Ramon, CA – February 6, 2020 – Bioventrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced it received renewal of the highest priority reimbursement in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System by achieving the NUB Status 1 [...]

San Ramon, Kalifornien – 22. Januar 2020 – BioVentrix, Inc., Hersteller des ersten transkatheter-basierten Systems zum linksventrikulären Remodeling nach Herzinfarkt, hat heute die Verlängerung der CE-Zulassung für das Revivent TCTM Transcatheter Ventricular Enhancement System zur Be-handlung von Herzinsuffizienz bis Mai 2024 bekannt gegeben.„Die Verlängerung der CE Zulassung ist nicht nur [...]

SAN RAMON, Calif. – January 22, 2020 – BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced the extension of its CE Mark for the Revivent TC™ Transcatheter Ventricular Enhancement System for heart failure to May 2024."The extension of our CE [...]

Study Published in European Journal of Heart Failure Shows Significant and Sustained Improvement in Heart Function, Symptom Relief and Quality of Life Using Less Invasive Left Ventricular Enhancement DeviceSan Ramon, CA – Dec. 04, 2019 – Bioventrix, Inc., developer of the first less invasive system for left ventricular remodeling, today [...]

San Ramon, CA, Nov. 19, 2019 -- BioVentrix, Inc., a privately-held company with a first-in-class, transcatheter-based structural heart device to treat heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation status for its Revivent TC™ Transcatheter Ventricular Enhancement System for [...]

San Ramon, CA, USA – Oct. 07, 2019 – BioVentrix, Inc. announced the first patient was enrolled and treated in the REVIVE-HF European study, a prospective multi-center, dual-arm randomized controlled study evaluating the treatment of ischemic cardiomyopathy induced heart failure with the Revivent TC™ System compared to Guideline-Directed Medical Therapy [...]

To demonstrate that treatment with the Revivent TCTM System is more effective than Guideline Directed Medical Therapy (GDMT) for the treatment of ischemic heart failure.San Ramon, CA, USA – Sept. 23, 2019 – The Revivent TCTM System has continued to deliver impressive results when evaluating post-market data in Europe. The [...]

He will be focused on growth of the Revivent TCTM TransCatheter Ventricular Enhancement System. San Ramon, CA, USA – Sept. 16, 2019 – BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), announced today that Pedro Marques has been named Vice President [...]

Chief Medical Officer for Europe and Chief Financial Officer named San Ramon, CA, USA – August 6, 2019 – BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), today announced two significant additions to its executive team.Thasee Pillay, MBChB has been named [...]